Stakeholder Interviews to Inform Best Practice for Public Facing COVID-19 Wastewater Dashboards

Publication date: Mar 25, 2024

Background: WW-based epidemiology is the detection of pathogens from wastewater, typically sewage systems. Its use gained popularity during the COVID-19 pandemic as a rapid and non-invasive way to assess infection prevalence in a population. Public facing dashboards for SARS-CoV-2 were developed in response to the discovery that RNA biomarkers were being shed in faeces before symptoms. However, there is not a standard template or guidance for countries to follow. The aim of this research is to reflect on how currently available dashboards evolved during the pandemic and identify suitable content and rationale from these experiences. Methods and Results: Interviews were carried out with implementers and users of dashboards for SARS-CoV-2 WW data across Europe and North America. The interviews addressed commonalities and inconsistencies in displaying epidemiological data of SARS-CoV-2, clinical parameters of COVID-19, data on variants, and data transparency. The thematic analysis identified WW dashboard elements that can facilitate standardization, or at least interoperability. These elements emphasise communication among developers under the same organization, open access for identified stakeholders, and data summarized with a time-intensive graphic analysis through normalizing at least by population. Simultaneous communication of clinical surveillance is recommended. More research is needed on flow and faecal indicators for normalization of WW data, and on the analysis and representation of variants. Discussion: WW dashboard development between 2020-2023 provided a real-time iterative process of data representation, and several recommendations have been identified. Communication of data through dashboards has the potential to support early warning systems for infectious diseases.

Concepts Keywords
Conducting Clinical
Covidpoops19 Cov
June Covid
Sewage Dashboard
Spacex Dashboards
Display
Doi
Medrxiv
Participants
Preprint
Public
Sars
Stakeholder
Stakeholders
Surveillance

Semantics

Type Source Name
disease MESH COVID-19
disease IDO infection prevalence
disease VO population
disease VO organization
disease VO time
disease IDO process
disease MESH infectious diseases
disease IDO pathogen
disease MESH infection
disease MESH polio
disease VO vaccination
drug DRUGBANK Nonoxynol-9
disease MESH asymptomatic infections
disease MESH emergencies
drug DRUGBANK Huperzine B
disease IDO country
disease VO frequency
disease IDO intervention
drug DRUGBANK Spinosad
disease VO USA
disease VO Imovax ID
disease IDO pathogen surveillance
disease VO Optaflu
disease MESH gastroenteritis
drug DRUGBANK Gold
drug DRUGBANK Ammonia
disease VO monthly
disease MESH endemic diseases
disease MESH uncertainty
disease VO vaccine
disease VO protocol
drug DRUGBANK Water
disease VO volume
disease MESH Emerging Infectious Diseases

(Visited 1 times, 1 visits today)